Premium
Combining bone morphogenetic proteins‐2 and ‐6 has additive effects on osteoblastic differentiation in vitro and accelerates bone formation in vivo
Author(s) -
Visser Rick,
Bodnarova Kristina,
Arrabal Pilar M.,
Cifuentes Manuel,
Becerra Jose
Publication year - 2016
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.35546
Subject(s) - bone morphogenetic protein 2 , bone morphogenetic protein , in vivo , mesenchymal stem cell , in vitro , microbiology and biotechnology , smad , bone morphogenetic protein 7 , materials science , bmpr2 , biology , phosphorylation , biochemistry , gene
While only two members of the bone morphogenetic protein subfamily (BMP‐2 and ‐7) are approved to be used in combination with collagen type I in orthopaedic surgery, other BMPs are known to also be highly osteoinductive. Although all the osteogenic BMPs signal through Smad‐1/‐5/‐8 phosphorylation, they show different preferences for the available BMP receptors. In this work we studied the effect of combining two osteogenic BMPs (‐2 and ‐6), which belong to different groups within the subfamily and have different affinities to the existing BMP receptors. Both the growth and in vitro differentiation of MC3T3‐E1 mouse preosteoblasts and rat bone marrow‐derived mesenchymal stem cells (MSCs) were studied, as well as in vivo ectopic bone formation when the BMPs were intramuscularly implanted in rats with collagen type I sponges as carriers. The results show that these two growth factors have additive effects on the osteoblastic differentiation of cells in vitro and that their combination might be helpful to accelerate in vivo osteogenesis while reducing the amount of each individual BMP used. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 178–185, 2016.